혈류 감염 검사 시장 예측(-2034년) : 제품 유형, 병원체 유형, 검사 방법, 기술, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Bloodstream Infection Testing Market is accounted for $7.9 billion in 2026 and is expected to reach $16.1 billion by 2034 growing at a CAGR of 9.3% during the forecast period. Bloodstream infection testing involves diagnostic procedures aimed at identifying microbial pathogens in the bloodstream. This testing utilizes various techniques, including blood cultures and molecular methods, to detect bacteria, viruses, or fungi causing systemic infections. It plays a crucial role in early identification, guiding appropriate treatment decisions and preventing the spread of infections, significantly impacting patient care and public health on a worldwide scale.

According to the U.S. National Library of Medicine, world's largest medical library, Bloodstream Infections (BSIs) are a leading global cause of disease and mortality. The incidence of BSIs has grown over time and the rates ranges from 122 to 220 cases per 100,000 people.

Market Dynamics:

Driver:

Rising cases of bloodstream infections worldwide

The alarming rise in bloodstream infections (BSIs) across the globe is acting as a potent fuel for the bloodstream infection testing market. This surge is attributed to factors like increasing antibiotic resistance, invasive medical procedures and an aging population that is more susceptible to infections. This growing demand for rapid and precise identification of causative pathogens is driving the market for advanced diagnostic technologies like rapid molecular tests and automated blood culture systems. Additionally, heightened awareness about healthcare-associated infections (HAIs) is prompting hospitals and clinics to invest in robust BSI testing protocols, further propelling the market's expansion.

Restraint:

High costs associated with advanced diagnostic technologies

Advanced diagnostic technologies offer faster and more accurate bloodstream infection testing, their high price tag acts as a major market restraint. These sophisticated tests often require expensive equipment, specialized technicians, and complex workflows, driving up costs for both healthcare providers and patients. This can limit their accessibility in resource-constrained settings and discourage their widespread adoption, hindering the potential benefits they bring to patient care.

Opportunity:

Awareness among healthcare professionals

A crucial opportunity lies in raising awareness among healthcare professionals within the bloodstream infection testing market. Currently, many practitioners lack sufficient knowledge about the latest testing methods or the urgency of early BSI detection. By educating doctors, nurses and other medical staff on the rapid identification and treatment benefits of advanced testing, the market can unlock significant growth potential, which can effectively tap into this lucrative opportunity and drive market expansion.

Threat:

Data security concerns

Bloodstream infection testing relies heavily on digital data, making it vulnerable to cyberattacks. Hackers could steal sensitive patient information or manipulate test results, impacting diagnoses and potentially harming patients. This raises concerns about data privacy, trust in test accuracy and potential legal repercussions that limit market expansion.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted bloodstream infection testing. Medical facilities faced challenges in prioritizing resources for COVID-19 testing, potentially reducing attention to routine testing for bloodstream infections. Additionally, infection control measures, increased patient loads, and altered healthcare practices strained laboratory capacities. Delayed or reduced testing for bloodstream infections during the pandemic might have affected timely diagnosis and treatment, potentially impacting patient outcomes and necessitating adaptations in testing strategies and healthcare delivery.

The instrument segment is expected to be the largest during the forecast period

The instrument segment is poised to secure the largest market share in the market due to the increasing prevalence of bloodstream infections. Automated blood culture systems, molecular diagnostic platforms, and mass spectrometers play pivotal roles in identifying pathogens swiftly. Additionally, continuous advancements in instrument technologies, such as improved sensitivity and specificity, bolster their prominence, making them the leading contributor to the market share for bloodstream infection testing.

The diagnostics laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostics laboratories segment is poised for significant growth due to increased awareness of preventive healthcare and amplified demand for diagnostic services. Technological advancements in diagnostics have led to more accurate and efficient testing methods, attracting more patients. Additionally, the rising prevalence of chronic diseases necessitates regular monitoring, boosting the need for diagnostic center services. Moreover, the COVID-19 pandemic emphasized the importance of accessible and efficient diagnostic facilities, fostering the expansion of diagnostics centers globally.

Region with largest share:

North America's dominance in the bloodstream infection testing market is owing to its advanced healthcare infrastructure and significant investments in research and development. Moreover, the presence of key market players, collaborations between industry and research institutions, and robust regulatory frameworks contribute to market growth. Additionally, the region's proactive adoption of innovative diagnostic technologies and heightened awareness about the importance of infection control further solidify North America's position in securing the largest market share.

Region with highest CAGR:

The Asia-Pacific region is positioned for significant growth due to rapid urbanization, increasing healthcare spending and expanding access to advanced medical technologies. Additionally, a growing population, rising awareness about health issues, and government initiatives supporting healthcare infrastructure development contribute to this trajectory. With a burgeoning middle class and evolving healthcare systems, the Asia-Pacific region presents immense opportunities for market expansion across various industries, including healthcare and diagnostics.

Key players in the market

Some of the key players in Bloodstream Infection Testing Market include Abbott Laboratories, Accelerate Diagnostics, Becton, Dickinson and Company (BD), Biocartis, BioMerieux, Bio-Rad Laboratories, Bruker Corporation, Cepheid, Danaher Corporation, DiaSorin, GenMark Diagnostics, Grifols, Hologic, Inc., Luminex Corporation, Molzym, OpGen, Qiagen, Roche Diagnostics, Sysmex Corporation and Thermo Fisher Scientific.

Key Developments:

In October 2023, Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. ('APIS'), a private UK based company specializing in molecular diagnostics, today announced the expansion of their partnership1 to include the commercialization of the APIS ESR1 Mutations Kit through Biocartis' worldwide commercial network.

In October 2023, Oxford Nanopore Technologies plc ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMerieux SA, a world leader in the field of in vitro diagnostics ("IVD") announced that bioMerieux is making an immediate £70M investment in Oxford Nanopore.

Product Types Covered:

• Instruments
• Consumables
• Services

Pathogen Types Covered:

• Bacterial Bloodstream Infections
• Fungal Bloodstream Infections
• Viral Bloodstream Infections

Testings Covered:

• Blood Culture Test
• Molecular Diagnostics
• Microbiological Testing
• Immunological Testing

Technologies Covered:

• Conventional Culture Technology
• Mass Spectrometry
• Microarray Technology
• Next-Generation Sequencing (NGS)
• Other Technologies

End Users Covered:

• Hospitals and Clinics
• Diagnostic Laboratories
• Academic and Research Institutes
• Point-of-Care Testing
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 End User Analysis
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Bloodstream Infection Testing Market, By Product Type

• 5.1 Introduction
• 5.2 Instruments
  • 5.2.1 Automated Blood Culture Systems
  • 5.2.2 Polymerase Chain Reaction (PCR) Instruments
• 5.3 Consumables
  • 5.3.1 Blood Culture Bottles
  • 5.3.2 Reagents
• 5.4 Software
  • 5.4.1 Data Analysis Software
  • 5.4.2 Reporting and Interpretation Software

6 Global Bloodstream Infection Testing Market, By Pathogen Type

• 6.1 Introduction
• 6.2 Bacterial Bloodstream Infections
• 6.3 Fungal Bloodstream Infections
• 6.4 Viral Bloodstream Infections

7 Global Bloodstream Infection Testing Market, By Testing

• 7.1 Introduction
• 7.2 Blood Culture Test
  • 7.2.1 Conventional Blood Culture
  • 7.2.2 Automated Blood Culture
• 7.3 Molecular Diagnostics
  • 7.3.1 Polymerase Chain Reaction (PCR)
  • 7.3.2 Nucleic Acid Amplification Techniques (NAAT)
• 7.4 Microbiological Testing
• 7.5 Immunological Testing

8 Global Bloodstream Infection Testing Market, By Technology

• 8.1 Introduction
• 8.2 Conventional Culture Technology
• 8.3 Mass Spectrometry
• 8.4 Microarray Technology
• 8.5 Next-Generation Sequencing (NGS)
• 8.6 Other Technologies

9 Global Bloodstream Infection Testing Market, By End User

• 9.1 Introduction
• 9.2 Hospitals and Clinics
• 9.3 Diagnostic Laboratories
• 9.4 Academic and Research Institutes
• 9.5 Point-of-Care Testing
• 9.6 Other End Users

10 Global Bloodstream Infection Testing Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Abbott Laboratories
• 12.2 Accelerate Diagnostics
• 12.3 Becton, Dickinson and Company (BD)
• 12.4 Biocartis
• 12.5 BioMerieux
• 12.6 Bio-Rad Laboratories
• 12.7 Bruker Corporation
• 12.8 Cepheid
• 12.9 Danaher Corporation
• 12.10 DiaSorin
• 12.11 GenMark Diagnostics
• 12.12 Grifols
• 12.13 Hologic, Inc.
• 12.14 Luminex Corporation
• 12.15 Molzym
• 12.16 OpGen
• 12.17 Qiagen
• 12.18 Roche Diagnostics
• 12.19 Sysmex Corporation
• 12.20 Thermo Fisher Scientific